RICHLAND, WASHINGTON – January 7, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori Woods will present at...
With over ten years of data on Cesium Blu, researchers continue to study its value in powering modern brachytherapy. ASTRO 2020 showcased multiple new e-posters and papers that can now be easily accessed online. A Matched Pair Analysis Of Clinical Outcomes...
Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World’s Premier Radiation Oncology Society RICHLAND, WASHINGTON – November 24, 2020 – The importance of Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate and brain...
Revenue Increased 3% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 104% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...
